Company intelligence / Profile preview

Neuralink

Fremont, California, United Statesneuralink.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Neuralink has successfully implanted its brain-computer interface device in a human patient as of January 2024. The first patient was able to control a computer mouse using thought alone. The company’s PRIME trial focuses on restoring digital communication and device control for people with severe paralysis. A second major program, Blindsight, aims to restore some vision in blind individuals and has received U.S. FDA breakthrough designation.

Therapeutic areas: OphthalmologyNeurology
Modalities: DeviceBrain-computer interfaceNeuroprosthetic device
Industry: Implantable Medical Devices

Beyond the preview

Go deeper on Neuralink.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neuralink.

Explore the full profile